WO2010082698A1 - 바이오액티브 물질코팅방법 및 튜브 - Google Patents
바이오액티브 물질코팅방법 및 튜브 Download PDFInfo
- Publication number
- WO2010082698A1 WO2010082698A1 PCT/KR2009/000282 KR2009000282W WO2010082698A1 WO 2010082698 A1 WO2010082698 A1 WO 2010082698A1 KR 2009000282 W KR2009000282 W KR 2009000282W WO 2010082698 A1 WO2010082698 A1 WO 2010082698A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- bioactive
- bioactive material
- tube
- solvent
- Prior art date
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 48
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 32
- 239000000463 material Substances 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 41
- 239000011248 coating agent Substances 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000012454 non-polar solvent Substances 0.000 claims abstract description 14
- 239000012046 mixed solvent Substances 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000002798 polar solvent Substances 0.000 claims abstract description 9
- 210000004204 blood vessel Anatomy 0.000 claims description 33
- 210000003462 vein Anatomy 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 238000001631 haemodialysis Methods 0.000 claims description 18
- 230000000322 hemodialysis Effects 0.000 claims description 18
- 210000001367 artery Anatomy 0.000 claims description 15
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 12
- 230000004087 circulation Effects 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 239000010409 thin film Substances 0.000 claims description 5
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 239000011149 active material Substances 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 210000000651 myofibroblast Anatomy 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 3
- 208000031481 Pathologic Constriction Diseases 0.000 abstract description 2
- 230000036262 stenosis Effects 0.000 abstract description 2
- 208000037804 stenosis Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract 3
- 239000011259 mixed solution Substances 0.000 abstract 1
- 239000002473 artificial blood Substances 0.000 description 18
- 230000002572 peristaltic effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000003363 arteriovenous anastomosis Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000013305 flexible fiber Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- -1 taclorimus Chemical compound 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D35/00—Filtering devices having features not specifically covered by groups B01D24/00 - B01D33/00, or for applications not specifically covered by groups B01D24/00 - B01D33/00; Auxiliary devices for filtration; Filter housing constructions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
- A61M1/3655—Arterio-venous shunts or fistulae
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2201/00—Details relating to filtering apparatus
- B01D2201/31—Other construction details
Definitions
- the present invention relates to a method of coating a bioactive material and a structure coated with the bioactive material.
- Korean Patent Registration Publication No. 10-0596218 (a tube for connecting arteriovenous veins of a hemodialysis patient treated with a drug) is a drug that inhibits cell proliferation and inflammation in artificial blood vessels made of expanded polytetrafluoroethylene (e-PTFE).
- e-PTFE expanded polytetrafluoroethylene
- e-PTFE is a thin film with micropores, which is obtained by stretching PTFE in various directions by extrusion at high temperature and high pressure. Since the coefficient of friction is very low, e-PTFE is delayed in adsorption of protein when it comes into contact with blood. It is used as a material for artificial blood vessels.
- FIG. 1 is a view showing the connection of arteries and veins of the artificial blood vessels undergoing hemodialysis, in order to perform arteriovenous fistula composition, a specific part of the body is cut into the subcutaneous area, and the arteries and veins in the incision site Both ends of the artificial blood vessel are joined to the perforated and perforated portions.
- the conjugated artificial blood vessel is closed at the incision site and is used as a channel for blood dialysis along with capillaries that connect the arteriovenous veins.
- a needle is connected from the hemodialysis machine to the blood between the artery and the vein.
- the catapult may be connected.
- hemodialysis is easy when peripheral tissues and artificial blood vessels are tightly coupled. Otherwise, bleeding may occur from artificial blood vessels after hemodialysis. Therefore, a certain amount of myofibroblast multiplies around the implanted artificial vessel and the artificial vessel should be fixed to the surrounding tissue.
- the present invention is to solve the above problems, the method of coating the drug on artificial blood vessels that can suppress the development of stenosis of artificial blood vessels and arteriovenous anastomosis, while proliferating myofibroblasts while reducing inflammation of surrounding tissues;
- the object is to provide a drug-coated artificial blood vessel.
- a method of coating a bioactive material in order to achieve the above object is to coat bioactive materials at different concentrations on at least one of an inner surface and an outer surface of a structure having a lumen.
- the structure is characterized in that both ends of the circulation passage of the human body is connected.
- the circulation passage of the human body is a blood vessel, and the blood vessels connected to both ends of the structure are characterized in that the artery and vein, respectively, is used as the vascular access path of the hemodialysis patient.
- one of the two or more solvents having different characteristics to be mixed in the mixed solvent is a polar solvent, the other is characterized in that the non-polar solvent.
- the polar solvent is water
- the non-polar solvent is characterized in that acetone.
- the bioactive substance is a drug that inhibits neointimal hyperplasia.
- bioactive material is characterized in that paclitaxel.
- the structure is characterized in that the thin film of e-PTFE having micropores.
- the tube is coated with different concentrations of the bioactive material on at least one of the inner surface and the outer surface of the structure having a lumen, the structure is a circulation passage and both ends of the human body It is characterized in that the connection.
- the circulation passage of the human body is a blood vessel
- the blood vessels connected to both ends of the structure are arteries and veins, respectively, characterized in that it is used as a vestibule approach path of the vascular dialysis patient.
- the bioactive substance is characterized in that the drug for inhibiting endometrial hyperproliferation.
- bioactive material is characterized in that paclitaxel.
- the structure is characterized in that the thin film of e-PTFE having micropores.
- the drug is coated only on the inner side in contact with blood of the arteriovenous connection tube used as an artificial blood vessel to reduce vascular stenosis, inflammation, thrombosis and neovascularization, and
- the outer side that is not in contact with the drug is not coated because the proliferation of myofibroblasts does not inhibit the effect that the adhesion to the surrounding tissues.
- FIG. 1 is a view showing a connection between the arterial and vein of the arteriovenous connection tuk is hemodialysis patients.
- Figure 2 is a cross-sectional view of the arteriovenous connection tube with the drug coated on the inside of the arteriovenous connection tube by the method according to the present invention.
- the present invention relates to a method of coating a bioactive material on a structure having lumens.
- the structure having lumens is connected to an artery and vein of a hemodialysis patient.
- the example used as a vascular access path is demonstrated.
- lumen refers to a lumen in a tubular organ, such as a blood vessel, or a lumen, such as a urethral canal.
- a lumen structure is collectively referred to as a tube. To explain.
- the structure having the lumen described above When the structure having the lumen described above is used for arteriovenous connection of the hemodialysis patient, as shown in FIG. 1, it can be used to connect arteries and veins. May occur. Therefore, in order to reduce the incidence of blood vessel constriction or inflammation around the tube and to allow the myobrobroblast to proliferate around the tube in order to fix the tube well in the arteries and veins, only the inner wall of the arteriovenous tube The drug should be coated as a bioactive material.
- the drug inhibits neointimal hyperplasia or thrombosis of blood vessels. That is, since the inside of the arteriovenous connection tube is in direct contact with blood, the drug is coated on the inside of the arteriovenous connection tube and the drug is not coated on the outside so as to proliferate myofibroblasts.
- the drug is dissolved in a solvent having an appropriate polarity and then perfused into the arteriovenous connection tube, wherein the arteriovenous connection tube is made of expanded polytetrafluoroethylene (e-PTFE). Because of this, nonpolar solvents such as acetone penetrate well, but polar solvents such as water do not penetrate well.
- e-PTFE expanded polytetrafluoroethylene
- the coating solution should be made in such a way that the drug is dissolved in a mixed solvent having a proper polarity by mixing a polar solvent and a non-polar solvent in a predetermined ratio.
- the coating solution in which the drug is dissolved flows into the intravenous connection tube, the coating solution penetrates into the intravenous connection tube and the drug is coated inside the intravenous connection tube.
- the solvent used as the nonpolar solvent may be used in addition to acetone, depending on the solubility of the drug, diethyl ether, ethyl acetate, dichloromethane, n-hexane, chloroform. Since the acetone described in the embodiment of the present invention has good volatility, when the coating solution in which the drug is dissolved penetrates into the inside of the arteriovenous connection tube, only the drug can be coated on the inside of the arteriovenous connection tube. That is, the solvent used as the nonpolar solvent is preferably a nonpolar solvent having good volatility, such as acetone, and the drug can be dissolved well.
- the arteriovenous connection tube is preferably made of e-PTFE, since e-PTFE is a flexible fiber material, when the coating solution flows through the arterial vein connection tube, if the ratio of the nonpolar solvent of the coating solution is high arteriovenous vein Although the coating solution penetrates the connection tube well, if the ratio of the nonpolar solvent is too high, the coating solution may flow out through the fine pores of the arteriovenous connection tube. Therefore, the polarity should be controlled well when making coating solution.
- the drug is made of paclitaxel, which is used as an anticancer agent, to make a mixed solvent and to flow the mixed solvent into an intravenous connection tube.
- the ratio of water is preferably 9: 1, 8: 2 or 7: 3. Adjusting the ratio of acetone and water is so low that the coating solution can penetrate deeper into the inner wall of the arteriovenous connection tube if the polarity of the coating solution is close to nonpolar. The higher the proportion of water, the higher the polarity of the coating solution, so that the coating solution penetrates only to the shallow portion of the arteriovenous connection tube, thus reducing the amount of drug coated.
- the drug can be used in addition to paclitaxel rapamycin, taclorimus, cyclosporine A, etc.
- the drug may be a drug that can suppress the narrowing of the blood vessels or the occurrence of inflammation.
- e-PTFE is made of a fiber material can be expanded by the pressure of the coating solution flowing inside, if the coating solution pressure is too high, the coating solution flows into the fine pores of the arteriovenous connection tube
- the pressure of the coating solution flowing through the arteriovenous connection tube should be well controlled.
- the peristaltic pump is perfused to the tube for arteriovenous connection at an appropriate pressure. That is, when percolating the coating solution to the arteriovenous connection tube using the peristaltic pump, the flow rate and time of the coating solution can be adjusted.
- the concentration of the drug in the coating solution is coated inside the arterial arterial connection tube. Can be adjusted. Of course, the lower the speed of the coating solution and the longer the coating solution flows, the higher the concentration of the coating solution drug is coated on the inside of the arteriovenous connection tube.
- the degree of coating is weakened as it is coated and toward the outside. Therefore, since the drug is coated on the inside of the tube and the drug is not coated on the outside, the growth of myofibroblasts is not suppressed while reducing the occurrence of narrowing of the arteriovenous anastomosis or inflammation of surrounding tissues. Thus, even when transplanted into the body, the proliferation of myofibroblasts is well established and fixed to surrounding tissues.
- the drug-coated tube of the present invention as an artificial blood vessel connecting with arteries or veins It can also be used, but it can also be connected to lymphatic vessels.
- drug-coated tubes can be used in diseases such as Critical Limb Ischemia, and in addition to being used as a vascular access pathway, alternative vessels such as Coronary Artery Bypass Graft (CABG). Can also be used as.
- CABG Coronary Artery Bypass Graft
- the present invention can be applied to the field of medical technology.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- External Artificial Organs (AREA)
- Prostheses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
- 루멘(Lumen)을 가지는 구조물의 내면과 외면 중 적어도 하나에 바이오액티브(Bioactive) 물질을 서로 다른 농도로 코팅하기 위해 상기 구조물의 내측으로 혼합용매에 상기 바이오액티브 물질이 용해된 코팅용액이 흐르는 과정을 포함하고,상기 혼합용매는 서로 다른 특성을 가지는 둘 이상의 용매가 혼합되는 것을 특징으로 하는 바이오액티브 물질코팅방법.
- 제1항에 있어서,상기 구조물은 인체의 순환통로와 양 끝단이 연결되는 것을 특징으로 하는 바이오액티브 물질코팅방법.
- 제2항에 있어서,상기 인체의 순환통로는 혈관이고,상기 구조물의 양 끝단이 연결되는 혈관은 각각 동맥 및 정맥으로, 혈액투석환자의 혈관접근경로로 사용되는 것을 특징으로 하는 바이오액티브 물질코팅방법.
- 제1항에 있어서,상기 혼합용매에 혼합되는 서로 다른 특성을 가지는 둘 이상의 용매 중 하나는 극성용매이고, 다른 하나는 무극성용매인 것을 특징으로 하는 바이오액티브 물질코팅방법.
- 제4항에 있어서,상기 극성용매는 물이고, 상기 무극성용매는 아세톤인 것을 특징으로 하는 바이오액티브 물질코팅방법.
- 제1항에 있어서,상기 바이오액티브 물질은 신내막 과증식(Neointimal Hyperplasia)을 억제하는 약물인 것을 특징으로 하는 바이오액티브 물질코팅방법.
- 제1항에 있어서,상기 바이오액티브 물질은 파클리탁셀(Paclitaxel)인 것을 특징으로 하는 바이오액티브 물질코팅방법.
- 제1항에 있어서,상기 구조물는 미세기공을 갖는 e-PTFE(Expanded Polytetrafluoroethylene)의 박막필름인 것을 특징으로 하는 바이오액티브 물질코팅방법.
- 루멘을 가지는 구조물의 내면과 외면 중 적어도 하나에 바이오액티브 물질이 서로 다른 농도로 코팅되고, 상기 구조물은 인체의 순환통로와 양 끝단이 연결되는 것을 특징으로 하는 튜브.
- 제9항에 있어서,상기 인체의 순환통로는 혈관이고,상기 구조물의 양 끝단이 연결되는 혈관은 각각 동맥 및 정맥으로, 혈관투석환자의 현관접근경로로 사용되는 것을 특징으로 하는 튜브.
- 제9항에 있어서,상기 바이오액티브 물질은 신내막 과증식을 억제하는 약물인 것을 특징으로 튜브.
- 제9항에 있어서,상기 바이오액티브 물질은 파클리탁셀인 것을 특징으로 하는 튜브.
- 제9항에 있어서,상기 구조물은 미세기공을 갖는 e-PTFE의 박막필름인 것을 특징으로 하는 튜브.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200980101072.2A CN101951971B (zh) | 2009-01-15 | 2009-01-19 | 生物活性物质涂覆方法及管 |
JP2010546689A JP5255656B2 (ja) | 2009-01-15 | 2009-01-19 | バイオアクティブ物質のコーティング方法およびチューブ |
EP09837224.6A EP2450068B1 (en) | 2009-01-15 | 2009-01-19 | Bioactive material coating method and tube |
US12/866,235 US8075940B2 (en) | 2009-01-15 | 2009-01-19 | Bioactive material coating method and tube |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090003472A KR101034654B1 (ko) | 2009-01-15 | 2009-01-15 | 바이오액티브 물질 코팅방법 |
KR10-2009-0003472 | 2009-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010082698A1 true WO2010082698A1 (ko) | 2010-07-22 |
Family
ID=42339937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/000282 WO2010082698A1 (ko) | 2009-01-15 | 2009-01-19 | 바이오액티브 물질코팅방법 및 튜브 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8075940B2 (ko) |
EP (1) | EP2450068B1 (ko) |
JP (1) | JP5255656B2 (ko) |
KR (1) | KR101034654B1 (ko) |
CN (1) | CN101951971B (ko) |
WO (1) | WO2010082698A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014010759A1 (ko) * | 2012-07-10 | 2014-01-16 | 주식회사 엠아이텍 | 인체에 삽입되는 루멘을 가진 원통형의 구조물 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102125470B (zh) * | 2011-01-30 | 2016-01-06 | 王嘉贤 | 支架型血管及将其植入人体的专用牵引工具 |
CN104027844A (zh) * | 2014-04-04 | 2014-09-10 | 张志辉 | 一种用黄芪多糖涂层人工血管的新方法 |
CN104096265B (zh) * | 2014-07-01 | 2016-03-23 | 温州医科大学 | 一种用于构建人工血管模型的三维收缩模型的制备方法 |
KR101812101B1 (ko) * | 2016-10-10 | 2017-12-26 | (주)메디파마플랜 | 인공혈관 내부 코팅장치 |
CN108947380B (zh) * | 2017-05-18 | 2021-02-12 | 京畿大学校产学协力团 | 使用多孔材料固定化菌剂和近中性粘结剂用于细菌粘液基涂覆材料的制造方法 |
KR102283339B1 (ko) * | 2019-06-27 | 2021-08-02 | 사회복지법인 삼성생명공익재단 | 생리활성물질이 코팅된 체내 이식용 인공혈관 및 그 코팅방법 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030045847A (ko) * | 2000-10-31 | 2003-06-11 | 쿡 인코포레이티드 | 코팅된 이식형 의료 장치 |
US20030113359A1 (en) * | 2001-01-16 | 2003-06-19 | Vascular Therapies, Llc | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
KR20030069326A (ko) * | 2002-02-20 | 2003-08-27 | 주식회사 엠티티 | 폴리테트라플루오르에틸렌 물질의 화학적 표면개질 방법 |
WO2003099169A1 (en) * | 2002-05-20 | 2003-12-04 | Orbus Medical Technologies Inc. | Drug eluting implantable medical device |
KR100596218B1 (ko) | 2004-06-10 | 2006-07-03 | (주)액세스 플러스 | 약물이 표면처리된 혈액투석환자의 동정맥 연결용 튜브 |
WO2007059253A2 (en) * | 2005-11-15 | 2007-05-24 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2986728B2 (ja) * | 1996-03-29 | 1999-12-06 | 株式会社人工血管技術研究センター | 人工血管 |
US7807210B1 (en) * | 2000-10-31 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
US20050220835A1 (en) * | 2004-03-30 | 2005-10-06 | Jayaraman Ramesh B | Agent eluting bioimplantable devices and polymer systems for their preparation |
US20060182777A1 (en) * | 2005-02-15 | 2006-08-17 | Steve Kangas | Method of modulating drug release from a coated substrate |
US20070286882A1 (en) * | 2006-06-09 | 2007-12-13 | Yiwen Tang | Solvent systems for coating medical devices |
-
2009
- 2009-01-15 KR KR1020090003472A patent/KR101034654B1/ko not_active IP Right Cessation
- 2009-01-19 CN CN200980101072.2A patent/CN101951971B/zh active Active
- 2009-01-19 JP JP2010546689A patent/JP5255656B2/ja active Active
- 2009-01-19 US US12/866,235 patent/US8075940B2/en not_active Expired - Fee Related
- 2009-01-19 EP EP09837224.6A patent/EP2450068B1/en active Active
- 2009-01-19 WO PCT/KR2009/000282 patent/WO2010082698A1/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030045847A (ko) * | 2000-10-31 | 2003-06-11 | 쿡 인코포레이티드 | 코팅된 이식형 의료 장치 |
US20030113359A1 (en) * | 2001-01-16 | 2003-06-19 | Vascular Therapies, Llc | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
KR20030069326A (ko) * | 2002-02-20 | 2003-08-27 | 주식회사 엠티티 | 폴리테트라플루오르에틸렌 물질의 화학적 표면개질 방법 |
WO2003099169A1 (en) * | 2002-05-20 | 2003-12-04 | Orbus Medical Technologies Inc. | Drug eluting implantable medical device |
KR100596218B1 (ko) | 2004-06-10 | 2006-07-03 | (주)액세스 플러스 | 약물이 표면처리된 혈액투석환자의 동정맥 연결용 튜브 |
WO2007059253A2 (en) * | 2005-11-15 | 2007-05-24 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014010759A1 (ko) * | 2012-07-10 | 2014-01-16 | 주식회사 엠아이텍 | 인체에 삽입되는 루멘을 가진 원통형의 구조물 |
Also Published As
Publication number | Publication date |
---|---|
EP2450068A1 (en) | 2012-05-09 |
CN101951971B (zh) | 2015-05-13 |
JP5255656B2 (ja) | 2013-08-07 |
EP2450068A4 (en) | 2013-12-25 |
JP2011509163A (ja) | 2011-03-24 |
US8075940B2 (en) | 2011-12-13 |
KR20100084059A (ko) | 2010-07-23 |
KR101034654B1 (ko) | 2011-05-16 |
CN101951971A (zh) | 2011-01-19 |
EP2450068B1 (en) | 2020-03-04 |
US20110029069A1 (en) | 2011-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010082698A1 (ko) | 바이오액티브 물질코팅방법 및 튜브 | |
US20060095121A1 (en) | Autologous platelet gel on a stent graft | |
US6086553A (en) | Arteriovenous shunt | |
CA2040708C (en) | Collapsible lumen catheter for extracorporeal treatment | |
US7473237B2 (en) | Apparatus for auto-retroperfusion of a coronary vein | |
US20040210236A1 (en) | Flow path control catheter with funnel-shaped expandable structure at proximal part and tubular-shaped structure at distal part and perfusion system with such a catheter | |
CA2589597A1 (en) | Methods and compositions for enhancing vascular access | |
JP2008522735A5 (ko) | ||
CA2580001A1 (en) | Apparatus and method for auto-retroperfusion of a coronary vein | |
US20140100510A1 (en) | Anastomotic connector | |
US20090155337A1 (en) | Method and agent for in-situ stabilization of vascular tissue | |
US5281662A (en) | Anthraquinone dye treated materials | |
EP1325756B1 (en) | Delivery source of oxygen and kit for producing a medical device | |
JP2007531594A (ja) | 薬剤を溶出する生体埋め込み型装置及び薬剤調製ポリマーシステム | |
US7833148B2 (en) | Lumen formation-inducible material and instrument to be inserted into the body | |
WO2018045797A1 (zh) | 覆膜支架及其制备方法 | |
WO2011040652A1 (ko) | 이식용 튜브 및 그의 코팅 방법 | |
US20080221660A1 (en) | Platelet Gel for Treatment of Aneurysms | |
US11077239B2 (en) | Tributary access device and methods of use | |
WO2018070591A1 (ko) | 인공혈관 내부 코팅장치 | |
WO2014010759A1 (ko) | 인체에 삽입되는 루멘을 가진 원통형의 구조물 | |
KR101119011B1 (ko) | 이식용 튜브 및 그의 코팅 방법 | |
CN200987710Y (zh) | 血透用人工血管窦 | |
KR101240437B1 (ko) | 인체에 삽입되는 루멘을 가진 원통형의 구조물 | |
WO2021080275A2 (ko) | 혈관 외벽 랩핑용 기구 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980101072.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010546689 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009837224 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12866235 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09837224 Country of ref document: EP Kind code of ref document: A1 |